Skip to main content
OpenTrials
Completed

NCT Number: NCT01961674

Studying the Effect of Capsinoids on Brown Fat Using Infrared Thermal Imaging.

The primary hypothesis of this study is that consumption of capsinoids increases brown adipose tissue activity, detectable by infrared thermal imaging.

The secondary hypothesis is that consumption of capsinoids can affect an individual's glycaemic response.

Completed

Looking for future studies?

Notify Me

Key information

About this study

It has been recently established that brown adipose tissue (BAT) exists in adult humans. BAT is a thermogenic tissue which dissipates energy as heat. The primary objective of this study is to use thermal imaging to assess the effect of capsinoids on BAT activity in adult humans, and whether there is a relationship between the increase in energy expenditure and BAT activity after capsinoids intake. The secondary objective is to investigate whether capsinoids will have an effect on an individual's glycaemic response. Lean, healthy male volunteers will be recruited. There will be two test sessions which are randomized, where subjects will consume either capsinoids or placebo capsules, and a standardized amount of white rice (equivalent to 50g carbohydrates). Indirect calorimetry will be used to assess energy expenditure before and after consumption of the test meal. Thermal imaging of supraclavicular BAT, the primary BAT depot in humans, will be undertaken using an infrared thermal camera to assess changes in BAT temperature. Blood glucose levels will be monitored by finger prick blood sampling method. This study aims to investigate whether capsinoids consumption leads to changes in BAT temperatures detectable by the infrared thermal camera, to confirm the feasibility of using thermal imaging as a rapid, noninvasive, and reproducible way of studying BAT activity thus providing a platform to advance research in this emerging field of human BAT.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chinese ethnicity
  • Male
  • Healthy
  • Age 21 - 30 years
  • BMI 18.0 - 22.9 kg/m2
  • Not on any prescribed medication
  • Infrequent spicy food or chilli user (less than 3 times per week)

Exclusion criteria

  • Smoker
  • Fasting blood glucose > 5.5 mmol/L
  • Resting blood pressure > 140/90 mmHg
  • Any major medical conditions including diabetes, hypertension, cardiovascular disease, thyroid disorders
  • Allergic or intolerant to foods presented in the study

Treatment and study plan

Capsinoid/placebo and rice

Dietary Supplement

The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.

Primary outcomes

  1. Temperature at supraclavicular region

    Time frame: 2.5 hours post-consumption

    The temperature at the supraclavicular region following consumption of capsinoids will be determined using infrared thermal imaging.

Secondary outcomes

  1. Glycaemic response

    Time frame: 2.5 hours post-consumption

    The blood glucose response to capsinoids measured over 2.5 hours following their consumption.

Sponsors and collaborators

Lead sponsor

Singapore Institute of Food and Biotechnology Innovation

Other Gov

Registry information

Official study title

Infrared Thermal Imaging for Assessing the Effect of Capsinoids on Brown Adipose Tissue Activity.

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Oct 11, 2013
Registry last updated
Feb 2, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.